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Background: Changes in CD4 cell counts are poorly documented in individuals with low or moderate-level viremia
while on antiretroviral treatment (ART) in resource-limited settings. We assessed the impact of on-going HIV-RNA
replication on CD4 cell count slopes in patients treated with a first-line combination ART.
Method: Naïve patients on a first-line ART regimen with at least two measures of HIV-RNA available after ART
initiation were included in the study. The relationships between mean CD4 cell count change and HIV-RNA at 6
and 12 months after ART initiation (M6 and M12) were assessed by linear mixed models adjusted for gender, age,
clinical stage and year of starting ART.
Results: 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a
median follow-up time of 1.6 years, a median age of 34 years, and a median CD4 cell count at ART initiation of 107
cells/μL. All patients with suppressed HIV-RNA at M12 had a continuous increase in CD4 cell count up to 18 months
after treatment initiation. By contrast, any degree of HIV-RNA replication both at M6 and M12 was associated with a
flat or a decreasing CD4 cell count slope. Multivariable analysis using HIV-RNA thresholds of 10,000 and 5,000 copies
confirmed the significant effect of HIV-RNA on CD4 cell counts both at M6 and M12.
Conclusion: In routinely monitored patients on an NNRTI-based first-line ART, on-going low-level HIV-RNA replication
was associated with a poor immune outcome in patients who had detectable levels of the virus after one year of ART.
Keywords: HIV-1, CD4 count, CD4 slope, HIV-RNA threshold, Resource limited settingsBackground
Antiretroviral Therapy (ART) has undoubtedly changed
lives, both in resource-rich and in resource-limited settings
(RLS). While a large majority of patients on antiretroviral
(ARV) drugs achieve sustained virological suppression,
some experience a treatment failure eventually leading to
treatment change. Treatment switches to second–line ARV
regimens in RLS occur at a lower rate than expected due to* Correspondence: acalmy@gmail.com
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reproduction in any medium, provided the orseveral constraints: limited access to virological monitoring,
limited availability of suitable ARV drugs, pill burden, tox-
icity and cost, thus limiting the use of second-line ART
regimens even in failing patients [1-4]. Overall, it is esti-
mated that second–line ART accounts for <5% of total
ARV use in RLS at the present time [5].
Currently, most treatment failures are diagnosed by a
CD4 cell count decrease, or by a clinical event as per the
2006 World Health Organization (WHO) guidelines [6].
Cohort analyses suggested that non-virological criteria
do not accurately predict virological failure [7,8].
Two randomised trials, (Home-Based AIDS Care [HBAC]
and Development of Antiretroviral Therapy in Africatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of monitoring strategies in RLS. A meta-analysis of these
two trials concluded that clinical monitoring alone (com-
pared to combined immunological and clinical monitoring
or to combined virological, immunological, and clinical
monitoring) resulted in unnecessary treatment switches,
disease progression, and increased mortality [11]. These
results were not confirmed by a recent study conducted in
Cameroon in which no differences between laboratory-
based or clinical strategies were demonstrated at 24 months
[12]. Another clinical trial in Thailand failed to demonstrate
a significant difference in clinical failure among patients
whose switching decision was based on CD4 cell counts
versus HIV-RNA at 3 years [13]. Nevertheless, newer
WHO recommendations do recommend using HIV-RNA
plasma viral load (HIV-RNA) to confirm a suspected treat-
ment failure [14].
The optimal threshold of HIV-RNA and the optimal fre-
quency of HIV-RNA determination that best inform anti-
retroviral switches in RLS are still being debated. In
Europe, Australia and the USA, most clinicians continue
to rely on the approach in which a virological failure is
defined by an HIV-RNA level above the detection thresh-
old; and complete viral suppression is the goal of ART,
with HIV-RNA level being monitored every three to six
months. Thus, the American guidelines and the guidelines
from various European countries all propose that HIV-
RNA detection is the essential tool by which to monitor
the need to switch ART [15,16].
This strategy of maximal viral suppression may be less
appropriate in a context in which the second-line treatment
may be considered as the last chance for a suppressive regi-
men. The PLATO study suggested that ART regimen that
maintains a viral load of <10,000 copies/ml was not asso-
ciated with an appreciable CD4 cell count decline in triple-
class experienced patients after a median follow-up period
of two years [17]. Similarly, an Italian cohort study on 3023
patients over a median clinical follow-up time of 46 months
showed that the risk of clinical progression was lower in
patients with moderate viremia (<10,000 copies/ml), com-
pared with patients with higher HIV-RNA levels [18].
We aimed to investigate the effect of on-going HIV-
RNA replication at low levels in routinely monitored
patients on a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI) based first-line ARV regimen in RLS. For this
purpose, we analysed changes in CD4 cell counts in
patients with an incomplete virological response or with a
virological failure to two ARV drug classes.
Methods
The ART-LINC of IeDEA collaboration
The Antiretroviral Therapy in Low-Income Countries
(ART-LINC) Collaboration is a network of antiretroviral
treatment programs in Africa, Latin America and Asia.This project has been reorganised in the International epi-
demiological Database to Evaluate AIDS (IeDEA) initiative
(http://www.iedea-hiv.org/). Data sources, the merging of
data and quality control procedures have been described
elsewhere [19]. Patient information in the pertinent data-
base is de-identified. This research has been carried out in
compliance with the Helsinki Declaration and Institutional
review boards in all countries approved the analysis of rou-
tinely collected programme data at all sites.Eligibility criteria and definitions
For this analysis, we selected from the IeDEA database all
HIV-1 infected naïve adults (16 years or older) with gen-
der and date of ART initiation known, treated with a
first–line ARV combination including two nucleoside ana-
logues (NRTIs) and one protease inhibitor (PI) or one
NNRTI. Patients needed to have an HIV-RNA measure-
ment at least six and 12 months after ART initiation (plus
or minus three months) and to have at least one CD4 cell
count measure between six months (or within the three
months before) and 18 months following ART commence-
ment. We excluded all patients with undetectable HIV-
RNA levels (<500 copies/ml) at ART initiation.
We examined the data for these subjects up to 18 months
after ART initiation or at the date of switch to a second-
line ARV regimen. Second-line ART was defined by at least
one therapeutic class modification and at least one NRTI
modification. A patient was considered lost to follow-up if
the patient was not known to have died and the time inter-
val between the last date he (she) was known to be alive
and the closure date of cohorts (i.e., date of last record) was
>6 months.Statistical analysis
We assessed the CD4 cell count response to treatment be-
tween six and 18 months after ART initiation, using linear
mixed models. The changes in CD4 cell count were mod-
eled with two slopes: the first slope was for the six to
12 months after ART initiation and the second slope was
for the 12 to 18 months after ART initiation. An intercept
at the initial time of the analysis (six months after ART
initiation) was also included in the linear mixed models.
To take into account the correlation of the repeated mea-
surements within each patient, the parameters were
allowed to vary from one patient to another through the
random intercept and the two random slopes. An unstruc-
tured covariance matrix was used for random effects,
allowing a correlation between the individual baseline level
and the slopes. To avoid any collider bias CD4 count
changes were not adjust for initial CD4 count as fixed
effects. We considered (a priori) three HIV-RNA thresh-
olds (500 [lower limit], 5,000 and 10,000 copies/ml [upper
limit]) 6 and 12 months after ART initiation.
ART-LINC total database 
N=45,800
Date of birth and gender known, age 16 
N=43,262
ART naïve and treated by 2NRTIs+1PI  
or 2NRTIs+1NNRTI 
N=36,327 
Viral load >500 copies/mL at ART initiation 
N=35,949
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of ART initiation, gender, year of starting ART and clinical
stage at starting ART. These adjustment factors were
included as main effects to adjust the intercept at six
months and as interactions with time to adjust CD4
slopes. HIV-RNA measured both at six and 12 months
after ART initiation were entered as covariates in the
model to estimate the effect of HIV-RNA on the first and
the second CD4 count slope respectively. We considered
40 year old (or older) women starting ART in 2004 or later
at clinical stage A, B (CDC classification) or I, II (WHO
classification) and with a viral load at M6 and M12 <500
copies/mL as the reference group. We compared mixed
models using these HIV-RNA thresholds with the Akaike
Information Criterion (AIC).
All analyses were performed using SAS version 9.1
(SAS Institute, Cary, North Carolina, USA).ART: Antiretroviral treatment 
NNRTI: Non-nucleoside reverse transcriptase inhibitor 
NRTI: Nucleoside reverse transcriptase inhibitor 
PI: Protease inhibitor
Viral load available at M6  
N=5,407 
Viral load available at M6 and M12 
N=3,352
At least 1 CD4 cell count measurement 
between M6 and M18  
N=3,338 
Figure 1 Study flow chart. ART-LINC of IeDEA Cohort
Collaboration.Results
Population
We included 3,338 patients from 14 different cohorts in
this analysis (Figure 1). The number of patients per cohort
ranged from 46 to 891, with nine cohorts from sub-
Saharan Africa (accounting for 80.1% of the overall study
population), three cohorts from Latin America (14.7%),
one cohort from Morocco and one from India. The patient
group had the following characteristics: 2,139 patients were
female (64.1%), the median age was 34 years (inter-quartile
range (IQR)= 30-41); 32.3% of the patients were in WHO
stage I or II at ART initiation; 2,070 (62.0%) patients
initiated their first-line ART in or after 2004; and for 96.0%
of the patients, the ART regimen included an NNRTI and
two NRTIs as per WHO recommendations. The follow-up
characteristics of the patient group are as follows: the total
number of person–years of follow-up was 6,778; the me-
dian follow-up time was 1.6 years (IQR=1.2-2.4); 3,039
patients (91.0%) were still followed up 12 months after
ART initiation and 1,995 (59.8%) were still followed up at
18 months; and 44 (1.3%) and 325 (9.7%) patients were lost
to follow-up at 12 and 18 months, respectively (Table 1).CD4 cell count and HIV-RNA: Data description
A majority of patients (83.9%) had three or more HIV-
RNA determinations during the study period. Similarly,
87.8% had at least three CD4 cell counts and 46.2% had
a greater number of measurements up to 18 months.
Median HIV-RNA level (log10) at ART initiation was
5.07 (IQR 4.53-5.54) and the median CD4 cell count was
107 cells/mm3 (IQR= 46-179); 3,038, 2,969 and 814 indi-
viduals had an HIV-RNA level below the threshold of
500 copies/ml at M6, M12 and M18, respectively, after
starting ART (91.0%, 89.0% and 87.7% of all available
viral load measurements, respectively).Among patients initiating ART with HIV-RNA levels
above 10,000 copies/ml, 91.7% (n = 1,780) and 90.0%
(n = 1,747) achieved HIV-RNA levels below 500 copies/
ml six months and 12 months, respectively, after ART
commencement. Among patients with undetectable
(<500 copies/ml) HIV-RNA levels (n = 3,038) at M6,
93.0% (n = 2,825) remained with an undetectable HIV-
RNA level and 3.0% (n = 92) had an HIV-RNA level
≥10,000 copies/ml at M12. Among patients with un-
detectable HIV-RNA levels six and 12 months after
starting ART (n = 2,825), 750 (94.1% of patients with
available data) remained with an undetectable HIV-RNA
at M18.
Table 1 Patient characteristics at ART initiation, and
during follow-up (ART-LINC of IeDEA, 2008, n = 3,338)
Characteristics at ART initiation N
Women (%) 2,139 (64.1)
Median age (IQR*) 34.0 (30–41)
Clinical stage (%)
WHO I/II or CDC A/B 1,078 (32.3)
WHO III 977 (29.3)
WHO IV or AIDS 1,019 (30.5)
Unknown 264 (7.9)
Year of starting ART (%)
1997 to 2001 351 (10.5)
2002 to 2003 917 (27.5)
2004 to 2005 1,629 (48.8)
2006 to 2007 441 (13.2)
First ART regimen (%)
2NRTIs + 1NNRTI 3,205 (96.0)
2NRTIs + 1PI 133 (4.0)
Median CD4 cell count (IQR) 107 (46–179)
HIV-RNA (%)
[500–10,000[ copies/mL 170 (5.1)
≥10,000 copies/mL 1,942 (58.2)
Unknown 1,226 (36.7)
Characteristics 6 months after ART initiation
Median CD4 cell count (IQR) 228 (158–325)
HIV-RNA (%)
<500 copies/mL 3,038 (91.0)
[500–10,000[ copies/mL 155 (4.6)
≥10,000copies/mL 145 (4.4)
Characteristics 12 months after ART initiation
Median CD4 cell count (IQR) 276 (192–383)
HIV-RNA (%)
<500 copies/mL 2,969 (89.0)
[500–10,000[ copies/mL 187 (5.6)
≥10,000 copies/mL 182 (5.4)
Median follow-up in years (IQR) 1.6 (1.2-2.4)
Median number of CD4 measurements (IQR) 2 (2–3)
Deaths at M18 (%) 18 (0.5)
Lost to follow-up at M18 (%) 325 (9.7)
* IQR = interquartile range.
ART: Antiretroviral treatment.
NNRTI: Non nucleoside reverse transcriptase inhibitor.
NRTI: Nucleoside reverse transcriptase inhibitor.
PI: Protease inhibitor.
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We assessed the effect of the HIV-RNA level while on
ART on the mean CD4 cell count slope. Figure 2-a
shows the adjusted mean CD4 cell count slopes (for the6 to 12 months period) of patients with an M6 HIV-
RNA level below or above a threshold of 10,000; Fig-
ure 2-c gives these slopes using an HIV RNA threshold
of 5,000. Figure 2-b shows the CD4 cell count slopes
(for the 12 to 18 months period) of patients with an
M12 HIV-RNA level below or above a threshold of
10,000; Figure 2-d shows the same slope for patients
with a 5,000 threshold. The CD4 cell count SLOPE was
not significantly different from the null value between
six and 12 months following ART initiation, regardless
of the HIV-RNA replication level (Figures 2-a, c). How-
ever, differences related to HIV-RNA replication levels
were observed after 18 months: only patients with sup-
pressed HIV-RNA levels at 12 months had a continuous
increase in CD4 cell count, whereas those with any de-
gree of HIV-RNA replication (either 10,000 or 5,000
copies) 12 months after ART commencement had either
no increase or a decrease of their CD4 cell count slope
(Figures 2-b, d).
Table 2 shows that age, sex, CDC stage, and the calen-
dar year in which ART was initiated were all significant
determinants of CD4 cell count six months after ART
initiation. Moreover, we modelled the effect of several
HIV RNA values at M6 and M12 following ART initi-
ation on the CD4 cell count changes between M6 and
M18; CD4 cell count increased by 90 cells (95% CI = 71;
108) per year when patients had a suppressed HIV-RNA
level at both M6 and M12; in contrast, CD4 cell count
decreased by 1 cell per year (CI =−51; 48) when HIV-
RNA was consistently above 10,000 copies (Table 2). In
addition, similar CD4 cell count changes were observed
when a lower HIV-RNA threshold (5,000 copies) was
chosen as a cut-off (AIC= 106669 for the 10,000 versus
106679 for the 5,000 copies threshold) [data not shown].
Discussion
Our data demonstrates that among patients initiating ther-
apy in RLS with (mainly) an NNRTI-based regimen, CD4
cell count recovery is impaired in the presence of on-
going HIV-RNA replication over an 18-month period. We
were not able to find a minimal HIV-RNA threshold
below which viral replication had no impact on immuno-
logical restoration. Our analysis showed an impact of
HIV-RNA replication at 12 months on the direction of the
CD4 cell count slope; thresholds of 10,000 or 5,000 copies
were equally predictive of the direction of the CD4 cell
count slope in the adjusted analysis.
Current ART guidelines recommend changing therapy
when virological failure occurs [14-16]. The WHO latest
recommendations reinforce the role of virological moni-
toring in informing the switching decision [14], a sub-
stantial change compared to the earlier versions. We
used data from a multicentre cohort collaboration cap-
turing routine data in various RLS on three continents,
34
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Figure 2 a: Mean CD4 cell count change between M6-M12 relative to the M6 viral load (adjusted, threshold = 10,000 copies/ml).
b: Mean CD4 cell count change between M12-M18 relative to the M12 viral load (adjusted, threshold = 10,000 copies/ml). c: Mean CD4 cell count
change between M6-M12 relative to the M6 viral load (adjusted, threshold = 5,000 copies/ml). d: Mean CD4 cell count change between M12-M18
relative to the M12 viral load (adjusted, threshold = 5,000 copies/ml).
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regular HIV-RNA and CD4 cell count monitoring. In
these patients, we confirmed that the percentage of
patients with short term virological success on an
NNRTI-based first-line therapy was excellent [20,21].
The optimal response to low or moderate-level viremia
in patients on ART in RLS has been controversial. Ana-
lyses performed in countries with regular and frequent
HIV-RNA monitoring and using PI-based ARV regimens
tend to suggest that the use of an HIV-RNA threshold of
5,000-10,000 copies/mL to define failure in a regimen-
adherent patient with no other reasons for an elevated
HIV-RNA (e.g., drug-drug interactions, poor absorption,
and concurrent illness) is not associated with clinical
and immunological deterioration in cohort studies
[17,18,22]. There are substantial differences between
patients in high-income countries and patients in RLS
that prevent us from generalising findings from Western
cohorts. Firstly, patients starting ART in RLS have much
lower CD4 cell counts at treatment initiation when com-
pared with high-income countries [23]. Secondly, most
first-line regimens include a combination of two nucleo-
side analogues (NRTI) and one NNRTI, unlike high-income countries in which half of new patients are put
on a boosted protease inhibitor-based ART. Finally, one
might infer that immunity is affected by numerous anti-
genic stimulations in countries endemic for malaria or
tuberculosis [24].
It is thus critical to accumulate data from countries
where the majority of patients are now receiving ART,
where the treatment switch is going to occur late and
where first-line ARV combinations are different from the
standard practice in high-income countries from where
most clinical guidelines have been issued.
Because the WHO now recommends using targeted or
sometimes routine use of HIV-RNA measurements in
public-health oriented programs, much effort needs to
go into making HIV-RNA determination available in
RLS. However, the cut-off describing when to switch
patients failing an NNRTI first-line regimen with few
remaining therapeutic options has not been firmly estab-
lished and depends on the objective: if the aim is to im-
pact on HIV transmission or to prevent viral resistance
[25-28], then viral load measurement has to be widely
implemented over all ART programs and the lowest
threshold must be used to inform the switching decision.
Table 2 CD4 count six months after ART initiation and CD4 changes estimated by adjusted linear mixed model,
relative to the viral load six and 12 months after starting ART (HIV-RNA threshold 10,000 copies), ART-LINC of IeDEA
Variables Mean CD4 cell count at M6 (cells/μL) 95% CI p value
Viral load at M6 <0.0001
<500 289* 277;301
[500–10,000[ (vs <500) −3 −26;+20
≥10,000 (vs <500) −82 −106;-58
Gender 0.0005
Male vs female −18 −29;+8
Age at starting ART (years) 0.0451
[16-30[ vs. ≥40 +13 −1;+27
[30-35[ vs. ≥40 −3 −16;+10
[35-40[ vs. ≥40 −7 −21;+7
Year of starting ART 0.0111
Prior to 2004 vs. up to 2003 +14 +3;+25
Stage at starting ART <0.0001
III vs. A,B/I,II −50 −62;-38
AIDS/IV vs. A,B/I,II −46 −58;-33
Unknown vs. A,B/I,II −5 −24;+14
Mean CD4 cell count change from M6 to M18 (cells/μL)
Viral load at M6 and M12* <0.0001
Viral load <500 at M6 and <500 at M12 +90 +71;+108
Viral load <500 at M6 and [500–10,000[ at M12 +49 +7;+91
Viral load <500 at M6 and ≥10,000 at M12 +1 −47;+49
Viral load = [500–10,000[ at M6 and <500 at M12 +64 +37;+90
Viral load = [500–10,000[ at M6 and = [500–10,000[ at M12 +23 −22;+68
Viral load = [500–10,000[ at M6 and ≥10,000 at M12 −25 −76;+26
Viral load ≥10,000 at M6 and <500 at M12 +87 +59;+115
Viral load ≥10,000 at M6 and= [500–10,000[ at M12 +46 0;+93
Viral load ≥10,000 at M6 and ≥10,000 at M12 −1 −51;+48
* For the reference group: up to 39 year old women, starting ART up to 2003 at clinical stage WHO I,II or CDC A,B with a viral load <500 copies/mL six months
after ART initiation.
ART: Antiretroviral treatment.
95% CI: 95% confidence interval.
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viral threshold below which the goal of maintaining a
reasonable level of CD4 cells and a good clinical out-
come is achievable without switching treatment.
In this large multicohort study, we observed that in
patients experiencing virological failure, the impact on im-
mune restoration was observed after the first year of ARV
treatment; CD4 cell count slope one year after ART initi-
ation was altered by any (even low-level) HIV-RNA repli-
cation, regardless of the threshold considered (5,000 or
10000 copies/mL). By contrast, all patients who had a sup-
pressed viral load 12 months after ART commencement
experienced a rise in CD4 cell counts (Table 2).
While our study lacked the statistical power necessary
to categorise what threshold would best stratify thedecision for changing ART regimens, our analysis sug-
gests that any viral replication had a deleterious impact
on immune recovery in patients remaining on a failing
first-line regimen.
Interestingly, patients who had residual HIV-RNA rep-
lication in the first six months on treatment, but were
then virologically suppressed at M12, experienced an im-
mune restoration with a positive CD4 cell count slope
from M6 up to M18. This could suggest that routine,
compared to random, viral load determination may
allow for therapeutic intervention leading to successful
immune restoration. Hoffmann et al. nicely showed that
patients on a first line regimen in South Africa who
developed viremia were successfully re-suppressed after
implementing intensive adherence support [29].
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ognition of failure in first line treatment has been contro-
versial in resource-limited settings. Seyler et al. showed in
Côte d’Ivoire that patients with a detectable viral load had
an increased risk of immunological failure, but there was
no difference in morbidity at 18 months between the
patients who switched during early regimen failure and
those who remained on a failing regimen [26]. In contrast,
other studies have shown that delays in switching to
second-line regimens resulted in increased mortality when
the failing regimen was a non-protease inhibitor-based
regimen [30]. More recently, Keiser et al. demonstrated
high mortality prior to and following a switch in treat-
ment in South Africa: the cumulative mortality at 1 year
was 4.2% (95% CI 2.2-7.8%) in patients who switched to
a second-line regimen, 11.7% (7.3%-18.5%) in patients
who remained on a failing first-line regimen, and 2.2%
(1.6-3.0%) in patients on a non-failing first-line regimen
(P< 0.0001). These results suggest that there are signifi-
cant consequences to delayed switching [31].
Our analysis also confirmed some interesting determi-
nants of the CD4 cell count slope; subjects with more ex-
treme ages (below 30 years old or above 40 years old) had
a better immune recovery when compared with the
middle-age group. Additionally, the calendar year of start-
ing ART and the stage at ART initiation were good predic-
tors of early immunological outcome. Considering an
HIV-RNA threshold of 10,000 copies/mL, which provided
in our multivariate model the best prognostic value for
immunological response, elevated HIV-RNA levels were
always associated with impaired immune reconstitution.
We recognise several limitations in our analysis.
Patients have been included in our study according to
the existence of frequent HIV-RNA monitoring, but only
a minority of patients fulfilled our criteria of biological
monitoring. Selection bias is therefore possible, although
we verified that none of the patients in our study had
entered specific therapeutic trial protocols but were ra-
ther prescribed viral load testing during specific periods
when this laboratory exam was available in the clinic. In
addition, we were unable to detect differences between
treatment regimens, as patients in RLS are generally pre-
scribed with standard NNRTI-based first-line regimens.
However, treatment homogeneity is helpful in control-
ling confounding factors related to different drug regi-
mens. Finally, we could not consider clinical endpoints,
as we had a very limited number of deaths in the
selected patient population, possibly due to the short
follow-up. For this reason, the clinical significance of the
differences in CD4 slope reported in our analysis cannot
be evaluated – although many cohorts from resource
limited settings clearly assessed the relationship between
AIDS-related events, non AIDS related events and death
and CD4 cells [32].Conclusion
Our data suggest that a failing regimen with documented
HIV-RNA replication should be switched onto a second-
line regimen, in line with recently issued WHO guidelines
requesting a decrease in the HIV-RNA threshold to in-
form the switching decision (from 10,000 copies in the
2006 guidelines down to 5,000 in the 2009–2010 revision
of the guidelines). We recognise that immune recovery is
not the only factor to consider regarding HIV disease
management in the short-term after ART initiation.
Whenever possible, HIV-RNA levels should be fully sup-
pressed, not only to prevent accumulation of resistance
mutations but also to prevent HIV transmission [28]. It is
therefore critical to promote access to low cost, context-
adapted viral load tools.
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